Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • News
    • Financial Results
    • Torrent Pharma Q4 net...

    Torrent Pharma Q4 net up 11 percent at Rs 228 crore

    Written by Ruby Khatun Khatun Published On 2018-06-01T10:30:51+05:30  |  Updated On 1 Jun 2018 10:30 AM IST
    Torrent Pharma Q4 net up 11 percent at Rs 228 crore

    New Delhi: Torrent Pharmaceuticals posted 11 percent increase in consolidated net profit at Rs 228 crore for the fourth quarter ended March 2018, driven by robust sales in domestic market.


    The company had reported a net profit of Rs 206 crore during the same period last year.


    Revenues for the fourth quarter rose to Rs 1,722 crore, as compared with Rs 1,434 crore in the January March period of 2016-17, Torrent Pharmaceuticals said in a regulatory filing.


    For the year ended March 31, 2018, the company posted a net profit of Rs 678 crore, down 27 percent from Rs 934 crore in 2016-17.


    Revenues during the year, however, rose by 2 percent to Rs 6,002 crore, compared with Rs 5,857 crore in 2016-17.




    During the year ended March 31, 2018, the company said its revenues in the domestic market grew by 19 percent to Rs 2,351 crore, as against Rs 1,976 crore in 2016-17.


    In the US market, the company said its revenues declined to 1,100 crore in 2017-18 as compared with Rs 1,346 crore in 2016-17.


    The company's board recommended a final dividend of Rs 5 per equity share of face value of Rs 5 each.

    dividendFinancial resultsfourth quarternet profitQ4revenuesTorrent PharmaTorrent Pharmaceuticals
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok